1/9
Looks like no tags are added yet.
ILO 1: List the four major Cyclin-CDK complexes, their cyclin/CDK partners, and their cell-cycle stages.
G1-Cdk: Cyclin D + Cdk4 / Cdk6 (acts in G1 in response to growth factors to drive cells past the G1 checkpoint). 2. G1/S-Cdk: Cyclin E + Cdk2 (acts in late G1 to trigger commitment at Start/R point and S-phase entry). 3. S-Cdk: Cyclin A + Cdk2 / Cdk1 (initiates and drives DNA replication in S phase). 4. M-Cdk: Cyclin B + Cdk1 (accumulates in G2 and triggers mitosis at the G2/M boundary).
ILO 1: List the three mechanisms that regulate Cyclin-CDK complex activity.
Phosphorylation and dephosphorylation (via CAK, Wee1, Cdc25, and downstream PP2A-B55). 2. Binding of CDK inhibitor proteins (CKIs such as p27, p21, and p16). 3. Timed synthesis and ubiquitin-mediated proteasomal degradation of cyclins.
ILO 1: Explain how CAK, Wee1, and Cdc25 regulate M-Cdk activity via phosphorylation and positive feedback.
ILO 1: Explain how PP2A-B55 and Greatwall kinase regulate downstream M-Cdk substrates during mitosis.
Protein phosphatase 2A (PP2A-B55) dephosphorylates downstream Cdk targets (such as Rb) to oppose Cdk activity and halt cell-cycle progression. During early mitosis, active M-Cdk phosphorylates Greatwall kinase, which phosphorylates Ensa; phosphorylated Ensa binds tightly to and inactivates PP2A-B55 so mitotic substrate phosphorylations are maintained.
ILO 1: Describe the roles of the CDK inhibitors (CKIs) p27, p21, and p16.
CKIs bind and suppress active cyclin-Cdk complexes: 1. p27: inhibits G1/S-Cdk and S-Cdk to help prevent cell-cycle entry (e.g., downstream of TGF-β). 2. p21: induced by p53 upon DNA damage in G1 to inhibit G1/S-Cdk and S-Cdk and arrest the cell cycle. 3. p16: inhibits G1-Cdk (Cyclin D-CDK4/6) and is frequently mutated/lost in human cancers.
ILO 1: Explain how timed cyclin synthesis and ubiquitin-dependent degradation ensure unidirectional cell-cycle progression.
CDKs remain at stable levels while cyclins rise and fall: Cyclins D and E carry PEST sequences (rich in Pro, Glu, Ser, Thr) for rapid turnover, whereas Cyclins A and B carry a destruction box. At the metaphase-to-anaphase transition, the activating subunit Cdc20 activates the E3 ubiquitin ligase APC/C, which polyubiquitinates M-cyclin (with E1/E2 enzymes) for degradation in the proteasome, dropping Cdk1 activity to trigger mitotic exit.
ILO 2: Explain how the retinoblastoma protein (Rb) controls progression from G1 into S phase.
In early G1, active (unphosphorylated) Rb binds and inhibits the transcription factor E2F, arresting the cell in G1. When Cyclin D-CDK4/6 (G1-Cdk) phosphorylates Rb, Rb changes conformation and releases E2F. Free active E2F transcribes S-phase genes—including Cyclin E (G1/S-cyclin) and Cyclin A (S-cyclin)—creating positive feedback loops in which G1/S-Cdk and S-Cdk further hyperphosphorylate Rb and E2F stimulates its own transcription to irreversibly drive DNA synthesis.
ILO 3: Explain how intrinsic DNA damage halts the G1 checkpoint via the p53–p21 pathway.
Normally, p53 is continuously expressed but kept low because Mdm2 ubiquitinates it for proteasomal degradation. DNA damage activates ATM/ATR and Chk1/Chk2 kinases, which phosphorylate and stabilize p53 so it dissociates from Mdm2. Active p53 binds the regulatory region of the p21 gene, inducing p21 transcription and translation; p21 binds and inhibits G1/S-Cdk and S-Cdk, arresting the cell in G1 for DNA repair (or triggering apoptosis if damage is irreparable).
ILO 3: Explain how extrinsic pro-proliferative (mitogenic) and anti-proliferative signals regulate the G1 checkpoint.
Cells require extracellular signals to divide; without them, cells withdraw into quiescence (G0) or undergo apoptosis. Pro-proliferative mitogens (e.g., Epidermal Growth Factor, EGF) bind cell-surface receptors and activate intracellular signalling that induces Cyclin D expression, activating CDK4/6 to phosphorylate Rb and release E2F. Anti-proliferative signals (e.g., TGF-β) induce CKIs such as p27 (and p16 inhibits CDK4/6), blocking CDK activity so Rb stays active and enforces G1 arrest.
ILO 4: Explain how disruption of the Rb–E2F axis contributes to cancer.
Nearly all human cancers involve disruption of G1 control. Loss-of-function mutations in Rb (first identified in childhood retinoblastoma), overexpression of Cyclin D, or loss of the